Travelling To India for Eye Care

Travelling to India for eye treatment? Travel for medical care is not simply about finding treatment. It is about finding the right diagnosis, understanding your options, and making important decisions with confidence. Dr Shibal Bhartiya provides specialist eye care for international patients seeking expert evaluation, second opinions, advanced diagnostics, and long-term management of complex eye conditions.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.

Expert Eye Care in India for Patients Seeking Clarity, Confidence, and Specialist Opinion

GlaucomaNeuro-OphthalmologyDry Eye & Ocular Surface DiseaseComplex Eye Care

Patients travel from the UK, USA, UAE, Singapore, Bangladesh, Nepal, East Africa, and across South Asia for consultations focused on careful assessment, evidence-based recommendations, and clear communication.

25+ Years Experience | 200+ Publications | 28 Textbooks | 1,500+ Five-Star Reviews | International Patients from 20+ Countries | 40000+ patients


Why International Patients Choose Dr Shibal Bhartiya

A Specialist Perspective for Complex Problems

Many patients seeking international consultations are not looking for another routine eye examination.

They are seeking answers to questions such as:

  • Am I actually progressing?
  • Do I really need surgery?
  • Why do my symptoms not match my test results?
  • Has something important been missed?
  • Why am I still struggling despite treatment?
  • Should I seek a second opinion before making a major decision?

Our consultations are designed to answer these questions through detailed evaluation, advanced diagnostics, and careful clinical interpretation.


Areas of Special Expertise

Glaucoma

Glaucoma is often diagnosed late because patients may continue seeing well while irreversible damage accumulates silently.

Dr Bhartiya’s glaucoma practice focuses on:

  • Early glaucoma diagnosis
  • Glaucoma suspects and risk assessment
  • Progression analysis
  • Normal tension glaucoma
  • Complex glaucoma management
  • Surgical decision-making
  • Second opinions before surgery
  • Long-term vision preservation strategies

Many international patients seek consultation after receiving conflicting advice or when they are uncertain whether treatment escalation is truly necessary.

You can read more about glaucoma here


Neuro-Ophthalmology

Neuro-ophthalmology bridges the gap between ophthalmology and neurology.

Common reasons for referral include:

  • Optic nerve disorders
  • Unexplained visual loss
  • Visual field abnormalities
  • Pituitary-related visual problems
  • Double vision
  • Intracranial hypertension
  • Neurological causes of visual symptoms
  • Complex diagnostic uncertainty

Patients are often referred after multiple consultations when symptoms, scans, and examinations do not fit together neatly.

You can read more about neuro-ophthalmology care here


Dry Eye & Ocular Surface Disease

Many patients with ocular surface disease have been treated repeatedly without understanding the underlying drivers of their symptoms.

Areas of focus include:

  • Chronic dry eye disease
  • Meibomian gland dysfunction
  • Ocular surface inflammation
  • Computer-related eye strain
  • Autoimmune ocular surface disease
  • Refractory dry eye
  • Ocular GVHD
  • Complex ocular discomfort syndromes

The goal is not simply prescribing more drops, but understanding why symptoms persist.

You can read more about ocular surface diseases including dry eye, and allergies, here


Comprehensive Ophthalmology & Diagnostic Second Opinions

Not every patient arrives with a diagnosis.

Many simply know that something is wrong.

We frequently evaluate patients seeking answers regarding:

  • Unexplained visual symptoms
  • Diagnostic uncertainty
  • Cataract and glaucoma overlap
  • Complex treatment decisions
  • Risk assessment before intervention
  • Long-term monitoring plans

Explore Our Specialist Eye Care Services

International patients often arrive with a diagnosis, a recommendation, or simply a concern that something is being missed.

While glaucoma, neuro-ophthalmology, and ocular surface disease are areas of particular expertise, every patient journey is different. Explore our specialist services below to better understand your condition and the options available.

Glaucoma Care

Glaucoma can cause permanent vision loss before symptoms become obvious. Learn about glaucoma diagnosis, risk assessment, progression monitoring, treatment options, and specialist second opinions.

Explore Glaucoma Care →


Neuro-Ophthalmology

Visual symptoms are not always caused by the eye itself. Neuro-ophthalmology evaluates disorders affecting the optic nerve, visual pathways, eye movements, and the connection between the eye and brain.

Explore Neuro-Ophthalmology →


Dry Eye & Ocular Surface Disease

Persistent irritation, burning, watering, fluctuating vision, and discomfort often require a deeper evaluation than routine eye examinations provide. Learn more about dry eye disease, meibomian gland dysfunction, ocular GVHD, and ocular surface disorders.

Explore Dry Eye & Ocular Surface Disease →


Second Opinions

Many patients seek reassurance before surgery, treatment escalation, or major decisions. A specialist second opinion can provide clarity, confirm a diagnosis, or identify alternative approaches.

Explore Second Opinions →


Advanced Diagnostic Testing

Accurate diagnosis depends on more than a single test result. Learn how OCT imaging, visual field analysis, optic nerve evaluation, and ocular surface assessment contribute to clinical decision-making.

Explore Advanced Diagnostics →


Comprehensive Eye Care

Not every patient arrives with a diagnosis. Some simply know that their vision has changed or that something does not feel right. Explore common eye conditions, symptoms, and specialist evaluation pathways.

Explore Comprehensive Eye Care →

Whether you are seeking a second opinion, treatment recommendations, or answers to a complex diagnostic question, our goal is to help you understand your condition clearly and make confident decisions about your eye health.

Popular Searches: glaucoma specialist India, neuro-ophthalmologist India, dry eye specialist India, glaucoma second opinion India, ocular surface disease specialist India, international eye specialist India, advanced eye care India, ophthalmologist for international patients.


International Patient Journey

Step 1: Send Your Records

Before travelling, patients may share:

  • Previous consultation notes
  • OCT scans
  • Visual field reports
  • MRI or CT reports
  • Surgical recommendations
  • Current medication lists

This allows preliminary review and helps ensure efficient use of consultation time.


Step 2: Pre-Visit Review

Records are reviewed before your appointment whenever possible.

This means consultations begin with context rather than starting from zero.


Step 3: Specialist Evaluation

Consultations may include:

  • Comprehensive examination
  • Advanced imaging
  • Functional testing
  • Risk assessment
  • Discussion of treatment options
  • Clarification of previous findings

Most investigations can be completed in a single visit.


Step 4: Written Clinical Opinion

Patients receive:

  • Detailed findings
  • Interpretation of investigations
  • Diagnosis (where possible)
  • Treatment recommendations
  • Follow-up strategy

Reports can be shared with treating doctors in the patient’s home country to support continuity of care.


Step 5: Ongoing Follow-Up

Many eye conditions require continuity rather than isolated intervention.

Where appropriate, follow-up planning may include:

  • Remote review of reports
  • Communication with local specialists
  • Monitoring recommendations
  • Long-term management planning

Why Patients Travel to India

India offers access to:

  • Advanced ophthalmic diagnostics
  • Internationally recognised specialists
  • Minimal waiting times
  • Comprehensive investigations in one location
  • Cost-effective care compared with many Western healthcare systems

Many patients are able to complete evaluation and decision-making within a short visit.


About Dr Shibal Bhartiya

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist with over 25 years of clinical experience. Her work combines clinical care, research, education, and international collaboration.

Highlights include:

  • Fellowship-Trained Glaucoma Specialist
  • Mayo Clinic Research Collaborator
  • 200+ Scientific Publications
  • 90+ PubMed-Indexed Papers
  • 28 Edited Textbooks
  • Editor-in-Chief, CLEVER
  • Executive Editor, Journal of Current Glaucoma Practice
  • International Speaker and Research Collaborator

Languages Spoken

To make complex medical discussions easier for international patients, consultations may be conducted with an interpreter, or facilitator if required. However, Dr Shibal Bhartiya speaks several languages:

  • English
  • Hindi
  • Urdu
  • French
  • Bangla (conversational)
  • Arabic (basic conversational)
  • Persian / Farsi (basic conversational)

Medical records and formal clinical documentation are provided in English, and may be provided in Hindi, French or Urdu on request .


Frequently Asked Questions

Can I send my reports before travelling?

Yes. Sharing reports beforehand helps determine what additional testing may be needed and allows more focused consultations.

Can I obtain a second opinion without surgery?

Absolutely. A large proportion of international patients seek clarity and confirmation before making treatment decisions.

How long should I stay in India?

Most second-opinion evaluations can be completed within 2–3 days. Surgical patients may require longer depending on the procedure.

Will my doctor at home receive a report?

Yes. With your permission, a detailed written opinion can be shared with your treating physician.

Do you assist with medical visa documentation?

Supporting medical documentation can be provided where required.


Send Your Reports Before You Travel

If you are considering travelling to India for glaucoma, neuro-ophthalmology, dry eye treatment, or a specialist second opinion, the process can begin before you leave home.

Send your reports, scans, or questions for review.

Dr Shibal Bhartiya
Glaucoma • Neuro-Ophthalmology • Advanced Eye Care • Second Opinion

🌐 www.drshibalbhartiya.com
📞 +91 88826 38735


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Ocular GVHD: Eye Problems After BMT

Ocular GVHD (Graft-Versus-Host Disease) is an immune-mediated condition that develops after a bone marrow or stem cell transplant. Donor immune cells attack the tear glands and eye surface, causing dry eyes, burning, redness, and light sensitivity. Early specialist evaluation and treatment protect the eye surface and preserve vision long-term.


Ocular GVHD affects your eyes after a bone marrow or stem cell transplant. Donor immune cells target your tear glands and corneal surface. The condition can appear weeks, months, or even years after transplant. Early identification changes outcomes significantly.

This condition sits at the intersection of haematology and ophthalmology. Your transplant team and your eye doctor need to work together. Regular eye review is part of post-transplant care, not an optional extra.


What Is Ocular GVHD?

Graft-Versus-Host Disease (GVHD) is an immune-mediated inflammatory reaction. It occurs when donor immune cells recognise the recipient’s tissues as foreign and attack them. Several organs can be affected, including the skin, liver, gut, and eyes.

The eye is more commonly affected in chronic GVHD, but acute GVHD can also involve the ocular surface. When the eyes are involved, the condition is called Ocular GVHD.


What Are the Symptoms of Ocular GVHD?

Symptoms range from mild to severe. They include one or more of the following:

  • Dry eyes and a persistent gritty sensation
  • Burning and irritation
  • Redness
  • Excessive watering and tearing
  • Light sensitivity
  • Blurred or fluctuating vision

In children, obvious complaints are often absent. Parents may notice excessive eye rubbing, light sensitivity, or reluctance to open the eyes in bright light.

Do not dismiss vague symptoms such as discomfort, scratchiness, or eye fatigue. These can be early signs of ocular GVHD. Your transplant surgeon may request an eye evaluation even when you have no symptoms at all.


How Is Ocular GVHD Diagnosed?

A complete eye examination is the starting point. This includes visual acuity testing, refraction, slit-lamp examination, and tear film assessment.

Your eye doctor will also perform specific tests to evaluate the ocular surface. These include the Schirmer’s test, and staining of the cornea with fluorescein and/or Rose Bengal dyes. These tests assess tear production and identify surface damage not visible to the naked eye.


How Is Ocular GVHD Treated?

Management focuses on controlling dryness, reducing inflammation, preventing infection, and protecting the cornea from scarring.

Systemic drugs given by your bone marrow transplant team for the rest of the body often do not adequately treat the eyes. Your eye doctor will likely recommend one or more of the following:

  • Lubricating eye drops to improve comfort and reduce corneal damage
  • Steroid eye drops to control inflammation and prevent scarring
  • Antibiotic eye drops to prevent or treat secondary infection
  • Autologous serum eye drops to support healing of the ocular surface
  • Cyclosporine eye drops to reduce the immune-mediated reaction

Treatment is adjusted over time based on disease activity and symptom burden. This is a condition that needs long-term follow-up, not a single course of treatment.


How is Ocular GVHD Classified?

Acute ocular GVHD develops during or soon after systemic acute GVHD and is characterized by sudden inflammation, redness, pain, tearing, photophobia, and conjunctival involvement.

Chronic ocular GVHD is a long-term immune-mediated disease that typically presents with persistent dry eye, burning, grittiness, fluctuating vision, meibomian gland dysfunction, and progressive ocular surface damage.

Acute-on-chronic ocular GVHD occurs when a patient with established chronic ocular GVHD experiences a sudden inflammatory flare, causing a rapid worsening of symptoms such as redness, pain, light sensitivity, and ocular surface inflammation on top of their baseline chronic dry eye disease.


Who Is Most at Risk?

Anyone who has undergone a bone marrow or stem cell transplant can develop ocular GVHD. Risk is higher in:

  • Patients with chronic GVHD affecting other organs
  • Patients on prolonged immunosuppression
  • Those with a history of acute GVHD

Children who have had transplants are a particularly vulnerable group. Symptoms may be subtle. Eye problems can quietly affect reading, school performance, and daily comfort without an obvious complaint from the child.


When to See a Specialist

See an eye specialist promptly if any of the following apply.

You or your child has had a bone marrow or stem cell transplant, and eye symptoms have appeared at any point after — not only in the early weeks.

Symptoms are present but mild. Mild ocular GVHD does not stay mild without treatment. Surface damage accumulates quietly.

Your transplant team has not yet arranged an ophthalmic review. Ask for one. It should be part of standard post-transplant follow-up.

Vision feels “off” even though a recent check showed normal acuity. Tear film instability affects functional vision. Standard acuity testing does not capture it.

You have been given lubricants but the symptoms persist. This is a signal for specialist evaluation, not a reason to try a different brand of drops.

What Doctors Sometimes Miss

Ocular GVHD is underdiagnosed. Several patterns come up repeatedly in practice.

Symptoms labelled as “just dry eyes.” Post-transplant dryness is not routine dry eye. The mechanism is different, the severity is higher, and the risk of corneal scarring is real. It needs specialist evaluation, not over-the-counter drops.

Children who don’t complain. A child who rubs their eyes, squints, or avoids reading is not always being difficult. These are ocular surface symptoms. Parents and transplant teams both need to watch for them.

The quiet chronic phase. Acute GVHD gets attention. Chronic ocular GVHD can smoulder for months with low-grade symptoms. Vision may remain measurably normal while the surface continues to deteriorate. Symptom absence does not mean the eye is safe.

Delayed referral from transplant teams. Eye review is sometimes requested only after symptoms become severe. Baseline ophthalmic evaluation before or shortly after transplant is better practice. Earlier review means earlier intervention.


Ocular GVHD: Symptoms, Causes, and When to Worry

SymptomWhat It MeansWhen to Worry
Dryness and grittinessTear gland damage from donor immune cellsIf persistent or worsening despite lubricants
Burning and irritationOcular surface inflammationIf affecting daily activities, reading, or sleep
RednessConjunctival involvementIf sudden, severe, or accompanied by pain
Light sensitivityCorneal surface damageIf debilitating or new after a settled period
Blurred or fluctuating visionTear film instability or corneal changesAlways warrants prompt specialist review
Eye rubbing in childrenMay be the only visible signIf post-transplant, refer early — do not wait
Watering and tearingReflex response to surface drynessIf combined with other symptoms

FAQs

Can ocular GVHD occur without dry eye symptoms?

Yes. Some patients present with redness, light sensitivity, or blurred vision rather than classic dryness. In children, the only sign may be eye rubbing or reluctance to be in bright light. A specialist examination is more reliable than symptom-based self-assessment.

Does ocular GVHD go away on its own?

Occasionally it settles with time, but many patients need long-term treatment. Stopping treatment early often leads to flare-ups. Your eye doctor will guide when and how to taper any medications.

Can both eyes be affected?

Yes. Ocular GVHD typically affects both eyes, though one side may be more symptomatic than the other.

Is teleconsultation available for ocular GVHD follow-up?

Yes. If you live outside Gurgaon or are unable to travel, teleconsultation is available to support ongoing management in partnership with your local eye doctor.


This page is part of the Dry Eye Disease hub. Read about our full approach to GVHD, dry eyes, and children’s eye care. Please also read the Pediatric Eye Care hub.

Here’s another heartening patient story: A young boy and his love for trucks, and Chronic GVHD and Success Stories.


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Read a patient story:

Ocular GVHD in Children

Chronic GVHD and Success Stories

Can Ocular GVHD Cause Dry Eyes?

Ocular GVHD is an eye condition that can develop after bone marrow or stem cell transplant, causing dry eyes, irritation, and fluctuating vision even after the main illness stabilises. Long-term follow-up helps protect the ocular surface, support daily function, and prevent slow, quiet damage from becoming permanent.

Here’s the story of a young girl’s grit and determination, as she battle GVHD. She is now a DOCTOR herself!!


She Came Back Every Holiday

A clinical story about ocular GVHD, dry eyes, and what it means to stay

Some patients stay in your memory because the diagnosis was rare.

Others stay because you realise, years later, that you were not just treating a condition. You were quietly watching somebody become who they were going to be.

I first met her when she was fifteen or sixteen. She had already been through more than most adults carry in a lifetime. She had undergone a bone marrow transplant. And afterwards, she developed ocular graft-versus-host disease — ocular GVHD.

Families who arrive after transplantation carry a particular kind of relief. The worst has happened. Treatment happened. Something enormous has been crossed. But uncertainty travels with them, because the body does not always stop at the finish line of the illness that was treated.

Then the eyes become part of the story.


What Ocular GVHD Feels Like From the Inside

Most people imagine ocular GVHD as something visibly dramatic. Sometimes it is. But for many patients, it arrives quietly.

Dryness that feels like something is always wrong, even on a good day. Burning that begins before the rest of the body feels tired. Vision that stays technically normal but no longer feels effortless.

Reading that becomes work. Studying that becomes slower. Screen time that was once easy and now costs something.

She was fifteen. She was trying to get back to school. She was trying to become a teenager again, the way teenagers are supposed to be — carelessly occupied with the future. And every day, her eyes made that harder.


Managing Ocular GVHD: What Actually Helps

Over the months that followed, we worked through treatment together. We managed her ocular surface carefully. We adjusted care as her symptoms changed. The active ocular GVHD gradually settled. Her vision got better. The comfort improved. Her reading improved. She got back to school.

But as so often happens with ocular GVHD, the story did not simply end when the acute phase resolved. She continued to have dry eyes. Frequent inflammation, sudden flare ups. Good months and difficult ones. The kind of low-grade, persistent vulnerability that does not make headlines but shapes ordinary days.

Steroids, in varying strengths, and frequency; lubricating eyedrops. Her BMT specialist and I, spoke about her thrice a day on some days, and some times, not even once a month.

She lived in Lucknow. Not nearby. And yet she kept coming back. Every few months. Then every holiday. Keeping in touch over the phone. Sometimes, just to talk. And we kept titrating her treatment to her symptoms, and to the disease activity.

Not because something dramatic was happening. Not because her vision was deteriorating. She came because follow-up had quietly become part of how she looked after herself. She understood, at sixteen, what many adults take years to learn: that a condition managed well is a condition you stop noticing.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google


What Patients Actually Remember

Doctors tend to think patients remember the treatment.

Patients usually remember something else. They remember whether someone recognised them the next time they walked in. They remember not having to explain everything from the beginning. They remember the quality of continuity more than the quality of any single intervention.

She sat her Class 12 examinations. Then she prepared for medical entrance exams.

One day she came to see me with her parents. Her eyes were stable. Her vision was good. She had come not because she needed treatment, but because she had received a medical school offer and wanted advice.

Which college. Which city. Whether to go far from home. We sat and talked. Years earlier we had been discussing tear films and corneal staining and drop regimens. Now we were discussing hostels and futures and what she wanted her life to look like.

She chose South India. She started medical school. Her parents were apprehensive because it was far away. Dr Shibal, she said, you can take care of me long distance, can’t you? I gave her a hug.

Your medical college will have an eye doctor, love. Yes, she said, but they’ll not be you.

And she still comes back. Every six months. Every holiday.

At one visit, she smiled and said something I still think about.

My vision is pristine.

I had to pause with that for a moment.

Because I do not think patients become doctors because someone cured them. I think sometimes they become doctors because someone stayed. Because someone showed them, over years of ordinary appointments, what it looks like to pay close attention to a person who is quietly carrying something.


This Is Not a Story About a Perfect Outcome

Her eyes still need looking after. She still struggles in difficult stretches. And is on medication. She still follows up.

But she built a life. She studied. And left home. She entered medicine. And every time she walks back into my clinic, I am reminded that the most important things in practice do not happen in the moments of diagnosis or surgery or crisis.

They happen in the reviews. The adjustments. The small, ordinary appointments where someone walks in and you already know who they are.

That is where medicine actually changes lives.

Last month, she graduated from medical school.


What Is Ocular GVHD?

Ocular graft-versus-host disease (ocular GVHD) is an eye condition that can develop after bone marrow or stem cell transplant. Donor immune cells may attack the tear glands and ocular surface, causing dryness, inflammation, and changes in visual comfort that persist long after the transplant itself has stabilised.

Symptoms can continue, fluctuate, or remain low-grade for years. Because of this, patients often benefit from long-term ophthalmic follow-up even when their systemic illness is well controlled and their measured vision remains good.

Symptoms of Ocular GVHD include:

Dry eyes, burning, irritation, fluctuating vision, redness, light sensitivity, watering, eye fatigue, difficulty reading or using screens for extended periods, and persistent ocular surface sensitivity that worsens with study, work, or environmental change.


How is Ocular GVHD classified?

Acute ocular GVHD develops during or soon after systemic acute GVHD and is characterized by sudden inflammation, redness, pain, tearing, photophobia, and conjunctival involvement.

Chronic ocular GVHD is a long-term immune-mediated disease that typically presents with persistent dry eye, burning, grittiness, fluctuating vision, meibomian gland dysfunction, and progressive ocular surface damage.

Acute-on-chronic ocular GVHD occurs when a patient with established chronic ocular GVHD experiences a sudden inflammatory flare, causing a rapid worsening of symptoms such as redness, pain, light sensitivity, and ocular surface inflammation on top of their baseline chronic dry eye disease.


When Should You See an Eye Specialist?

If you or your child has undergone a bone marrow or stem cell transplant and you notice persistent dryness, redness, fluctuating vision, burning, or discomfort — do not assume this is simply part of recovery.

The ocular surface can remain affected even after systemic disease feels far behind you. Early evaluation may preserve comfort, function, and long-term visual quality.

Known for her structured approach to vision risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.


This page is part of the Dry Eye Disease hub . Read about our full approach to GVHD, Dry Eyes and children’s eye care. Please also read Pediatric Eye Care hub

Here’s another heartening patient story: A young boy and his love for trucks


FAQs:

What is ocular GVHD?

Ocular GVHD is a complication that can develop after bone marrow or stem cell transplant. Donor immune cells affect the tear glands and eye surface, causing dryness, inflammation, and visual discomfort that may persist long after the main transplant illness stabilises.

What are the common symptoms?

Dry eyes, burning, fluctuating vision, redness, irritation, light sensitivity, watering, difficulty reading, and visual fatigue that worsens with screens or study.

Can ocular GVHD improve over time?

Yes. Many patients improve significantly, particularly with consistent treatment and close follow-up. Some continue to experience low-grade dryness or surface sensitivity for years. This does not mean the condition is untreatable — it means it requires sustained attention rather than a single course of treatment.

Can patients with ocular GVHD study, work, and live normally?

Many can, particularly when symptoms are identified early and managed consistently. The goal of treatment is not only to protect vision but to restore the quality of everyday life — reading, screens, study, and all the things that ordinary days are made of.

Why is long-term follow-up important?

Symptoms and underlying ocular surface health do not always change in parallel. A patient may feel stable and still have ongoing surface changes that benefit from monitoring. Regular review allows treatment to be adjusted before problems compound.

Does ocular GVHD affect children and young people differently?

The condition affects children and adolescents at a time when study load, screen use, and daily reading demands are high. Symptoms that an adult might manage around can significantly affect a young person’s academic performance and sense of normalcy. Recognising this early changes what the follow-up plan should look like.

About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Ocular Graft Versus Host Disease in Children

Ocular GVHD (Graft-versus-Host Disease) can cause severe dry eyes, burning, fluctuating vision, light sensitivity, and damage to the eye surface after a bone marrow or stem cell transplant. Early diagnosis and long-term eye care may help protect comfort, vision, and quality of life.

Managing these cases requires specialised corneal expertise, strict protective isolation compliance, and a deeply trauma-informed approach to pediatric clinical examination. Scientific precision alone is not enough — the child must feel safe enough to let you in.


Beyond the Sterile Barrier: Pediatric Ocular Graft-Versus-Host Disease

There are moments in a pediatric ophthalmologist’s career that anchor you for life.

During my time at Fortis, I cared for a tiny boy fighting for his life after a bone marrow transplant. Severe, acute Ocular GVHD had left his corneas damaged, covered in countless microscopic raw spots — Superficial Punctate Keratitis — causing blinding pain and extreme light sensitivity. He lived in the ICU, unable to open his eyes, afraid of every sound.

His immune system was almost non-existent. Anyone entering his space had to be covered head to toe in sterile gowns and masks. He could not see my face. He was terrified. Some days, he was too weak to cry.

To help him recognise me without triggering fear, I started a routine. Every time I entered his isolation pod, I whistled softly. He learned quickly. The whistle meant safety. No needles. It meant the person coming was not going to hurt him.

I would apply a careful drop of anaesthetic to numb the intense surface pain just enough to let me examine his corneas and adjust his treatment. And I kept talking. Through every protocol, every follow-up, every barrier-gowned visit, a bond formed between us.

His parents would quietly hold him. Silently, patiently, with all the love in the world.

Can GVHD be cured?

That was the only question they asked. For the pain to go away. I would say yes, he will be fine. And pray, silently.

And then one day, instead of crying, he started talking. About trucks, and JCBs and construction. All of five. And bright. And happy. Like any other five year old.

The drops continued, but he was now walking into my OPD, showing off his toys, his jeans, his shoes which have red and blue lights. And one day, we didn’t need any medication at all.

Today, he is completely cured — a bright, healthy boy, a handful and a half. Goes to big school. And to Goa with his grandparents. Collects toy trucks, especially likes yellow ones.

When he walks into my clinic, he does not see masks or sterile gowns. He sees a friend. He spots me from across the waiting room and runs full tilt into my arms. And talks till my ears hurt. And my face hurts. From smiling so much.

His parents recently told me that when they return to his BMT hospital for follow-ups, he looked up at the first floor where my old OPD used to be and insisted: “Let’s go meet Dr Shibal.” They had to remind him gently that I have moved. When he visited me at Marengo Asia after that, he looked around the new clinic and said, with complete satisfaction: “Dr Shibal, you always own the first floor.”

He is entirely right. Just like he owns my entire heart.

PS: Two of his classmates have come to me to get their glasses checked. Apparently he tells everyone about “My doctor” who has a hundred toffees. My little advertising blitzkreig he is 🙂


FAQs

What is Ocular GVHD in children, and what are the symptoms?

Ocular GVHD occurs when donor immune cells after a bone marrow transplant attack the recipient’s lacrimal glands and corneal surface. In children, symptoms include severe eye pain, redness, a gritty sensation, extreme light sensitivity, and refusal to open the eyes due to corneal surface damage. Early specialist intervention is critical to prevent permanent scarring.

What are the most common symptoms of ocular GVHD in adults?

Symptoms may include dry eyes, burning, redness, watering, irritation, light sensitivity, fluctuating vision, eye fatigue, and a feeling of grit or sand in the eyes.

Can ocular GVHD affect vision permanently?

If untreated, ocular GVHD can lead to chronic surface damage, discomfort, and vision changes. Early treatment and regular follow-up may reduce the risk of long-term complications.

How is ocular GVHD diagnosed?

Diagnosis is based on symptoms, eye examination, tear film assessment, evaluation of the eye surface, and correlation with transplant history and systemic GVHD status.

What treatments are available for ocular GVHD?

Treatment may include preservative-free lubricants, medicines to reduce inflammation, tear conservation strategies, ocular surface support, and long-term monitoring depending on severity.

How is severe pain and photophobia managed in post-transplant pediatric patients?

Management is multi-layered and highly specialised. It includes preservative-free lubricants, autologous serum eye drops, therapeutic scleral or bandage contact lenses, and targeted topical immunomodulators. During acute flares, topical anaesthetics are used carefully during examination by the specialist — never for unsupervised home use — to allow assessment without causing further distress to the child.


This page is part of the Pediatric Eye Care hub. Read about our full approach to children’s ophthalmology. Please also read Dry Eye Disease

Here’s another heartening patient story: the young girl who is now a doctor herself!


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google


Dry Eye Treatment in Gurgaon

Many people with dry eye are told their eyes are “normal” even while struggling with burning, fluctuating vision, eye strain, or discomfort during screen use. Advanced dry eye evaluation looks beyond redness alone to understand tear film instability, ocular surface disease, and the real-world visual symptoms affecting daily life.

Dry eye disease is not simply a lack of tears. It is a chronic condition of the ocular surface — driven by tear film instability, inflammation, meibomian gland dysfunction, or environmental exposure — that causes persistent discomfort, visual fluctuation, and in some cases, measurable damage to the surface of the eye. Effective management requires identifying which component is driving your symptoms, not simply prescribing lubricant drops.


Dry Eye Disease in Gurgaon: When Your Eyes Never Feel Quite Right

Dry eye is one of the most undertreated conditions in ophthalmology, not because treatment doesn’t exist, but because patients are routinely told that what they are experiencing is minor.

It is not minor. Eyes that burn, sting, water excessively, feel gritty by afternoon, blur when you are tired, or ache after two hours of screen time are not eyes that are functioning normally. And patients who have been handed a bottle of artificial tears and sent home, sometimes repeatedly, know exactly how inadequate that response feels.

Dry eye disease has a pathophysiology. It has subtypes. It has measurable signs. And it has a treatment pathway that goes considerably further than lubricant drops, when it is managed by someone who understands the full picture.

This practice takes dry eye seriously. Because your eyes deserve to feel comfortable.


What Dry Eye Disease Actually Is

Dry eye disease is a multifactorial condition of the ocular surface. The tear film — the thin, layered fluid that coats your eye with every blink — requires three components to function correctly: an aqueous layer produced by the lacrimal gland, a lipid layer produced by the meibomian glands in your eyelids, and a mucin layer produced by goblet cells on the ocular surface.

When any of these components fails, the tear film becomes unstable. The surface dries between blinks. Inflammation follows. And a self-reinforcing cycle begins — surface damage drives more inflammation, which drives more surface damage.

Understanding which component is failing is the starting point of effective treatment.

Evaporative dry eye and meibomian gland dysfunction

The most common form of dry eye in urban Indian populations is evaporative — driven by meibomian gland dysfunction (MGD). The meibomian glands line the upper and lower eyelids and produce the lipid layer that prevents tear evaporation. When these glands become blocked or atrophied, tears evaporate too quickly regardless of how much aqueous is produced.

MGD is dramatically worsened by screen use, air conditioning, low humidity environments, and contact lens wear — the exact conditions that define urban professional life in Gurgaon and Delhi NCR.

Aqueous deficient dry eye

In some patients — particularly post-menopausal women, patients with autoimmune conditions like Sjögren’s syndrome, and those on certain systemic medications — the lacrimal gland simply does not produce enough aqueous tears. This form requires a different treatment approach and often warrants systemic investigation.

Mixed dry eye

Many patients have both components — inadequate lipid and inadequate aqueous — compounded by surface inflammation. These patients are frequently the ones who have tried multiple lubricant drops without relief, because no single drop addresses the full picture.

Ocular surface inflammation

Chronic inflammation is both a cause and a consequence of dry eye disease. In patients with significant inflammation, lubricant drops alone will never be sufficient. Anti-inflammatory therapy — whether topical cyclosporine, lifitegrast, or short-course steroids — is a necessary component of management.


Why Dry Eye Is Worse Than Ever in Urban India

The epidemiology of dry eye has shifted dramatically in the last decade. What was once considered a condition of older women is now presenting across all ages, genders, and occupations — and the drivers are environmental and behavioural.

Risk FactorWhy It Matters
Screen timeBlink rate drops by up to 60% during screen use; tear film destabilises
Air conditioningLow humidity environments accelerate tear evaporation
Contact lens wearDisrupts tear film distribution and lipid layer integrity
Glaucoma dropsPreservatives in long-term glaucoma medications cause surface toxicity
Post-surgical drynessLASIK, cataract surgery, and other procedures transiently or persistently disrupt corneal nerves and surface
Hormonal changesMenopause significantly reduces aqueous and lipid tear production
Antihistamines and antidepressantsMany systemic medications reduce tear secretion as a side effect
Urban air pollutionParticulate matter and pollutants directly damage the ocular surface

Gurgaon sits at the intersection of several of these factors simultaneously — screen-intensive professional culture, year-round air conditioning, high ambient pollution, and one of the highest LASIK procedure rates in North India.


What We Often Miss in Dry Eye Management

Meibomian gland dysfunction goes unexamined. Most dry eye consultations do not include eyelid margin assessment or meibomian gland expression. Without examining the glands, evaporative dry eye — the most common subtype — is routinely misidentified as aqueous deficiency and treated with the wrong drops.

Post-surgical dryness is underestimated. Dry eye after LASIK, SMILE, or cataract surgery can persist for twelve to eighteen months, and in some patients becomes a chronic condition. Patients are frequently told their symptoms will resolve on their own — without a structured management plan being put in place.

Glaucoma patients’ ocular surface is neglected. Patients on long-term preserved glaucoma drops develop surface toxicity at a rate that is well-documented in the literature but poorly addressed in clinical practice. If you have glaucoma and dry eye, the two conditions must be managed together.

Inflammation is not addressed. Patients cycling through artificial tear brands without improvement almost always have a significant inflammatory component. Without anti-inflammatory therapy, the cycle does not break.

Screen habits are not discussed. Behavioural modification — structured blink exercises, the 20-20-20 rule, screen positioning, humidifier use — forms a critical part of dry eye management that is rarely covered in a brief consultation.


What to Expect at a Dry Eye Consultation

A structured dry eye assessment goes beyond asking how your eyes feel and prescribing drops.

At this practice, assessment includes tear film evaluation, tear break-up time, meibomian gland assessment, corneal and conjunctival staining, and a detailed history of your screen habits, contact lens use, surgical history, and systemic medications. Where indicated, additional investigations including meibography — imaging of the meibomian glands — may be recommended.

Treatment is then built around your specific subtype and severity. This may include targeted lubricants, lipid-containing drops, warm compress and lid hygiene protocols, anti-inflammatory therapy, punctal plugs, or in-office procedures. You will leave with a structured plan — not a single bottle and a follow-up in six months.


Dry Eye Topics Covered in This Practice

Understanding Dry Eye

Specific Populations

Treatment and Management

  • Dry eye drops: which one is right for your subtype
  • Anti-inflammatory treatment for chronic dry eye
  • Punctal plugs: what they are and when they help
  • Warm compresses and lid hygiene: the evidence base
  • Treatment-resistant dry eye: what to do when drops aren’t enough

Second Opinions

  • Getting a dry eye second opinion in Gurgaon
  • When dry eye symptoms mean something more serious

Here is what you can read, to understand your symptoms

Dry Eye Is Not Just Dryness

Dry Eye Specialist in Gurgaon

Natural remedies

Omega-3 and Dry Eye

Why Do Women Get Dry Eye More Often?

Women’s Eye Health

Why Dry Eye Is Worse in Air Conditioning and on Flights

Screen time and fatigue

Why Your Eyes Water Constantly

Diabetes and Eye Complications

Eye Health After 60

Eye Care During Pregnancy

Dry Eye

Autologous Serum Eye Drops for Severe

Dry Eye

Dry Eye Disease: A Chronic Eye Disease

Dry Eyes: Natural Remedies

Dry Eyes: Tips to Soothe Sore Eyes

Managing Glaucoma Eye Drop Side Effects

Menopause and Dry Eyes

Ocular GVHD & Its Implications

PROWL: Listening to LASIK Patients

Why Are Your Dry Eye Drops Not Working

Why Dry Eye Symptoms and Tests Don’t Match


When to Come In

Book a dry eye assessment if:

  • Your eyes burn, sting, or feel gritty — especially by afternoon or after screen use
  • Your vision fluctuates and clears when you blink
  • Your eyes water excessively — paradoxical tearing is a common dry eye sign
  • You wear contact lenses and your comfortable wearing time has reduced
  • You have had LASIK, SMILE, or cataract surgery and your eyes have not felt normal since
  • You are on long-term glaucoma drops and your eyes feel uncomfortable
  • You have been using lubricant drops for months without meaningful relief
  • You have been diagnosed with an autoimmune condition and have eye symptoms

Dry eye is a chronic condition — but it is a manageable one. The patients who do best are those who receive an accurate subtype diagnosis early and follow a structured management plan. Lubricant drops are a starting point, not a solution.


Frequently Asked Questions

What is the best treatment for dry eye disease?

There is no single best treatment — because dry eye has multiple subtypes that require different approaches. Evaporative dry eye from meibomian gland dysfunction is treated with warm compresses, lid hygiene, and lipid-containing drops. Aqueous deficient dry eye may require anti-inflammatory therapy and punctal plugs. Inflammatory dry eye requires targeted anti-inflammatory treatment. Accurate subtype diagnosis is the essential first step.

Can dry eye be cured permanently?

In most patients, dry eye disease is a chronic condition that requires ongoing management rather than a one-time cure. However, with consistent and correctly targeted treatment, the majority of patients achieve significant and sustained relief. Some causes — such as post-surgical dryness or medication-related dryness — may resolve once the underlying cause is addressed.

Why do my eyes water if I have dry eye?

Paradoxical tearing — excessive watering in a dry eye patient — is one of the most common and confusing symptoms of dry eye disease. When the ocular surface becomes irritated from tear film instability, the lacrimal gland produces reflex tears as a protective response. These reflex tears do not replace the stable tear film and do not relieve the underlying dryness.

Is dry eye worse in Gurgaon and Delhi NCR?

Yes. Urban environments with high screen use, year-round air conditioning, significant ambient pollution, and low outdoor humidity create conditions that are particularly hostile to tear film stability. Gurgaon’s professional demographic — high screen exposure, frequent air travel, contact lens use — compounds these environmental factors significantly.

Can dry eye damage my vision permanently?

In mild to moderate dry eye, vision fluctuates but does not sustain permanent damage. In severe, untreated dry eye — particularly in aqueous deficient conditions or after significant surface damage — corneal scarring and permanent visual reduction can occur. This is rare but preventable with appropriate management.

I have been using artificial tears for months with no improvement. What should I do?

This is the most common presentation at a dry eye second opinion consultation. Patients cycling through lubricant drop brands without relief almost always have either an unaddressed inflammatory component, undertreated meibomian gland dysfunction, or a subtype mismatch between the drops they are using and the dry eye they actually have. A structured reassessment — including eyelid examination and tear film evaluation — usually identifies the gap quickly.


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation for glaucoma

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google